Non-Consolidated Financial Statements of

ROYAL COLUMBIAN HOSPITAL FOUNDATION

And Independent Auditor's Report thereon Year ended March 31, 2023



KPMG LLP 32575 Simon Avenue Abbotsford, BC V5H 4M2 Canada Telephone (604) 854-2200 Fax (604) 853-2756

INDEPENDENT AUDITOR'S REPORT

To the Directors of Royal Columbian Hospital Foundation

Report on the Audit of the Non-Consolidated Financial Statements Opinion

We have audited the non-consolidated financial statements of the Royal Columbian Hospital Foundation, (the "Entity"), which comprise:

- the non-consolidated statement of financial position as at March 31, 2023
- the non-consolidated statement of operations and changes in net assets for the year then ended
- the non-consolidated statement of cash flows for the year then ended
- and notes to the non-consolidated financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2023, and its non-consolidated results of operations and its non-consolidated cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of
 expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the
 planned scope and timing of the audit and significant audit findings, including any
 significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

As required by the Societies Act (British Columbia), we report that, in our opinion, the accounting policies applied in preparing and presenting financial statements in accordance with Canadian accounting standards for not-for-profit organizations have been applied on a basis consistent with that of the preceding year.

Chartered Professional Accountants

Abbotsford, Canada June 28, 2023

LPMG LLP

Non-Consolidated Statement of Financial Position

March 31, 2023, with comparative information for 2022

	2023	2022
		(note 3
Assets		
Current assets:		
Cash and cash equivalents (note 4)	\$ 9,469,989	\$ 2,905,349
Accounts receivable	169,141	23,658
Prepaid expenses	229,723	39,226
Due from Fraser Health Authority (note 13)	5,357	7,228
	9,874,210	2,975,461
Tangible capital assets (note 6)	419,024	434,849
Investments (note 5)	31,264,911	31,071,628
Investment in Fraser Clinical Trials (note 7)	835,763	750,089
Life insurance policy (note 12)	11,404	11,404
	\$ 42,405,312	\$ 35,243,431
Liabilities and Net Assets		
Liabilities and Net Assets Current liabilities:		
	\$ 327,221	\$ 260,524
Current liabilities:	\$ 327,221 369,631	
Current liabilities: Accounts payable and accrued liabilities		422,252
Current liabilities: Accounts payable and accrued liabilities	369,631	422,252
Current liabilities: Accounts payable and accrued liabilities Due to Fraser Health Authority (note 13)	369,631	422,25 <u>2</u> 682,776
Current liabilities: Accounts payable and accrued liabilities Due to Fraser Health Authority (note 13) Net assets:	369,631 696,852	422,252 682,776 11,813,515
Current liabilities: Accounts payable and accrued liabilities Due to Fraser Health Authority (note 13) Net assets: Unrestricted	369,631 696,852 8,976,562	422,252 682,776 11,813,515 21,153,465
Current liabilities: Accounts payable and accrued liabilities Due to Fraser Health Authority (note 13) Net assets: Unrestricted Externally restricted (note 8)	369,631 696,852 8,976,562 31,091,491	422,252 682,776 11,813,515 21,153,465 1,593,675
Current liabilities: Accounts payable and accrued liabilities Due to Fraser Health Authority (note 13) Net assets: Unrestricted Externally restricted (note 8)	369,631 696,852 8,976,562 31,091,491 1,640,407	\$ 260,524 422,252 682,776 11,813,515 21,153,465 1,593,675 34,560,655

See accompanying notes to non-consolidated financial statements.

Approved on behalf of the Board:			
12-	_ Director	Me	_ Director

Non-Consolidated Statement of Operations and Changes in Net Assets

Year ended March 31, 2023, with comparative information for 2022

		Exter	nall	y Restricted Fu	nds				
				Designated			Endowment	2023	2022
	Unrestricted	Capital Fund		Fund		Total	Fund	Total	Total
_									(note 3)
Revenue:									
Donations	\$ 1,747,897 \$	-	\$	14,621,299	\$	14,621,299 \$	5,355	\$ 16,374,551 \$	13,002,114
Gaming income	257,245	-		91,363		91,363		348,608	289,895
Hospital parking lot	300,000	-		-		-	-	300,000	700,000
Investment income (note 10)	396,984	6,884		104,027		110,911	1,977	509,872	1,472,323
Equity loss from investment in									-
Fraser Clinical Trials Inc. (note 7)	85,674	-		-		-	-	85,674	244,625
Other income (note 7)	176,419	-		-		-	-	176,419	101,581
	2,964,219	6,884		14,816,689		14,823,573	7,332	17,795,124	15,810,538
Expenses:									
Amortization	15,664	-		-		-	-	15,664	15,733
Consulting and legal	658,887	2,651		35,409		38,060	762	697,709	370,847
Donor recognition and development	445,528	-		38,079		38,079	-	483,607	228,136
Office, stationery and miscellaneous	411,999	-		744		744	-	412,743	399,368
Postage and direct mail	42,095	-		-		-	-	42,095	41,323
Salaries, benefits and personnel services	2,359,189	-		206,699		206,699	-	2,565,888	2,483,063
Strata fees & property taxes	18,726	-		-		-	-	18,726	19,592
	3,952,088	2,651		280,931		283,582	762	4,236,432	3,558,062
Excess (deficiency) of revenue over expenses									
before contributions	(987,869)	4,233		14,535,758		14,539,991	6,570	13,558,692	12,252,476
Contributions to support Fraser Health									
Authority (note 13)	(733,599)			(5,677,288)		(5,677,288)	-	(6,410,887)	(8,280,888)
Excess (deficiency) of revenue over expenses									
and contributions	(1,721,468)	4,233		8,858,470		8,862,703	6,570	7,147,805	3,971,588
Net assets, beginning of year	11,813,515	5,634,432		15,519,033		21,153,465	1,593,675	34,560,655	30,589,067
Interfund transfers (notes 9(a) and 16)	(1,115,485)	-		1,075,323		1,075,323	40,162	-	-
Net assets, end of year	\$ 8,976,562 \$	5,638,665	\$	25,452,826	\$	31,091,491 \$	1,640,407	\$ 41,708,460 \$	34,560,655

See accompanying notes to non-consolidated financial statements.

Non-Consolidated Statement of Cash Flows

Year ended March 31, 2023, with comparative information for 2022

	2023	2022
		(note 3)
Cash and cash equivalents provided by (used in):		
Operating:		
Excess of revenue over expenses and contributions Items not involving cash:	\$ 7,147,805	\$ 3,971,588
Amortization	15,664	15,733
Unrealized loss on investments	1,226,276	521,512
Realized gain on investments	(159,714)	(201,512)
Equity gain from investment in Fraser Clinical Trials Inc.	(85,674)	(244,625)
Accrued interest income included in investments	-	67,616
	8,144,357	4,130,312
Changes in non-cash operating working capital:	-, ,	,,-
Accounts receivable	(145,483)	32,835
Prepaid expenses	(190,497)	2,643
Accounts payable and accrued liabilities	66,697	20,445
Due from Fraser Health Authority	1,871	(337)
Due to Fraser Health Authority	(52,621)	283,535
	7,824,324	4,469,433
Investments:		
Purchase of investments	(2,665,447)	(8,953,288)
Proceeds on sale of investments	1,405,602	4,405,089
Proceeds on disposal of tangible capital assets	161	-
	(1,259,684)	(4,548,199)
Decrease in cash and cash equivalents	6,564,640	(78,766)
Cash and cash equivalents, beginning of year	2,905,349	2,984,114
Cash and cash equivalents, end of year	\$ 9,469,989	\$ 2,905,349

See accompanying notes to non-consolidated financial statements.

Notes to the Non-Consolidated Financial Statements

Year ended March 31, 2023

1. Operations:

Royal Columbian Hospital Foundation (the "Foundation") is incorporated under the Societies Act (British Columbia). The Foundation's principal purpose is to fund, facilitate and promote high quality patient care through the provision of financial support for development, education and research at Royal Columbian Hospital. The Foundation receives gifts, bequests, funds and property which, in partnership with Fraser Health Authority (the "Authority"), are used to enhance the role of Royal Columbian Hospital. The Foundation is a registered charity under the Income Tax Act (the "Act") and accordingly, is exempt from income taxes provided certain requirements of the Act are met and is authorized to issue donation receipts for income tax purposes.

On April 1, 2022, the Foundation amalgamated with Queen's Park Healthcare Foundation ("QPHF"). The amalgamation was accounted for as a merger (note 3). The primary purpose of QPHF was to raise funds for the Queen's Park Care Centre to provide rehabilitation excellence for patients on their journey to recovery and supportive care within a living environment for seniors unable to live at home.

2. Significant accounting policies:

(a) Basis of presentation:

These non-consolidated financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations.

(b) Fund accounting:

In order to ensure observance of the limitations and restrictions placed on the use of resources available, the Foundation follows the restricted fund method of accounting for contributions. Under this method, restricted contributions are recorded as revenue of the restricted fund to which they relate. Accordingly, resources are classified for accounting and reporting purposes into funds. These funds are held in accordance with the objectives specified by the donors or in accordance with directives issued by the Board of Directors (the "Board"). For financial reporting purposes, the accounts have been classified into the following funds:

(i) Unrestricted:

The unrestricted fund reflects the results of operating activities and includes undesignated revenue and donations received by the Foundation.

(ii) Externally restricted:

The externally restricted funds include donations and other funding received by the Foundation which has been designated for specific purposes by the donor or funder.

(iii) Endowment:

The endowment fund comprises donations that are permanently maintained in accordance with donor wishes. The annual investment income earned from these endowments is used for specific purposes, in a manner consistent with the endowment agreement.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

2. Significant accounting policies (continued):

(c) Cash and cash equivalents:

Cash and cash equivalents include cash on hand and short-term deposits which are highly liquid with original maturities of less than three months at the date of acquisition. These financial assets are convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

(d) Investments:

Short-term investments are comprised of investments with original terms to maturity of less than one year at the date of purchase. Fixed income investments maturing after one year from date of purchase and pooled investments with no maturity date are classified as long-term investments.

The Foundation applies the equity method as a basis of accounting for its investment in Fraser Clinical Trials Inc. ("FCT"), a controlled profit-oriented enterprise. Under the equity method, the Foundation records its investment initially at cost and the carrying amounts are adjusted thereafter to include FCT's post-acquisition earnings. The adjustments are included in the determination of excess of revenue over expenses and contributions by the Foundation, and the corresponding investment account is also adjusted accordingly. Dividend distributions received or receivable from FCT reduce the carrying amount of the investment.

(e) Tangible capital assets:

Tangible capital assets are stated at cost, less accumulated amortization. Amortization of the building is provided on a straight-line basis over its estimated useful life of 30 years.

Repairs and maintenance costs are charged to expense. Betterments which extend the estimated life of an asset are capitalized.

Tangible capital assets are reviewed for impairment whenever events or changes in circumstances indicate that the asset no longer has or has reduced long term service potential to the Foundation. If such conditions exist, an impairment loss is measured at the amount by which the carrying amount of the asset exceeds its fair value or replacement cost.

(f) Revenue recognition:

The Foundation follows the restricted fund method of accounting for contributions. The capital fund includes the principal of donations received for capital projects and 10% of the investment income earned on the funds to maintain the principal. The endowment fund includes the principal of endowment donations and 10% of the investment income earned on the funds to maintain the principal. The designated fund includes all other restricted revenues and 90% of the investment income earned on the capital fund and endowment fund which is available to distribute to support the Authority in accordance with specific restrictions.

Contributions are recognized as revenue in the appropriate fund in the year received or receivable if the amount to be received can be reasonably established and collection is reasonably assured.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

2. Significant accounting policies (continued):

(f) Revenue recognition (continued):

Investment income is recognized when earned.

Hospital parking lot revenue is unrestricted and recognized when earned, the amount can be reasonably estimated, and collection is reasonably assured.

- (g) Combinations of not-for-profit organizations and adoption of new accounting standard:
 - (i) No party to the combination is characterized as either the acquirer or acquiree, either by its own Board or Management or by that of the other party to the combination.
 - (ii) Those charged with governance of the predecessor organizations participate in determining the terms of the combination. This includes establishing the governance and management structures of the combined organization and in selecting management personnel.
 - (iii) Except for transaction costs, no significant consideration flows to a third party of the organizations combining to form the reporting entity. A merger generally is accomplished by combining all of the assets and liabilities of the combining entities into a single reporting entity, without a transfer of cash or other assets to a third party of the reporting entity.
 - (iv) When entities combine, the reporting entity must encompass the purposes of each of the not-for-profit organizations subject to the combination at the combination date. While a combination may result in minor changes to the purpose of the combining not-for-profit organizations, a significant change would result in this criterion not being met.
 - (ν) At the combination date, there is no significant decline or planned significant decline in the client communities served by one or more but not all of the organizations that combined to form the reporting entity.

A combination of not-for-profit organizations under common control is accounted for as a merger. If all of the criteria are not met, the combination is accounted for as an acquisition.

(h) Contributed materials and services:

Contributed materials are recorded at their fair market values where the amount is reasonably determinable, and the items would otherwise have been acquired.

Volunteers contribute an indeterminate number of hours to assist the Foundation in carrying out its activities. Because of the difficulty of determining their fair value, contributed services are not recognized in the non-consolidated financial statements.

(i) Measurement uncertainty:

The preparation of the non-consolidated financial statements requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the non-consolidated financial statements and the reported amounts of revenue and expenses during the reported period.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

2. Significant accounting policies (continued):

(i) Measurement uncertainty (continued):

Estimates are based on the best information available at the time of preparation of the non-consolidated financial statements and are reviewed annually to reflect new information as it becomes available. Actual results could differ from those estimates.

(j) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Freestanding derivative instruments that are not in a qualifying hedging relationship, and equity instruments that are quoted in an active market, are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Foundation has not elected to carry any other instruments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Foundation determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Foundation expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

(k) Allocation of expenses:

The Foundation incurs costs to secure and manage gifts, provide recognition and manage the investment of the restricted funds. Accordingly, the Foundation allocates the costs of Foundation activities incurred up to 15% of any restricted fund donations received in the year to externally restricted funds, when agreed to by the donor.

(I) Life insurance policies:

Life insurance policies are recorded at the cash surrender value. Premiums are expensed as incurred. Any final pay-out received is recognized as revenue when realized.

(m) Employee future benefits:

The Foundation and its employees contribute to the Municipal Pension Plan. Defined contribution plan accounting is applied to the multi-employer defined benefit plan and, accordingly, contributions are expensed when paid or payable.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

3. Amalgamation with Queen's Park Hospital Foundation

On April 1, 2022, the Foundation and QPHF amalgamated and continued the combined operations under the name of Royal Columbian Hospital Foundation. The amalgamation occurred to form a single organization to increase impact in local communities and share resources.

As there is no identified acquirer in the amalgamation of the Foundation and QPHF, as of the amalgamation date, the assets, liabilities, and net assets of the entities became the combined carrying values of the assets, liabilities, and net assets of the Foundation. The financial statements of the entities were combined to form the current year figures and comparative figures as if the two entities had been combined from inception. There were no adjustments resulting from alignment of accounting policies of the two entities.

The following is a summary of the assets, liabilities and net assets of each of the entities as at the amalgamation date of April 1, 2022:

April 1, 2022	RCHF	QPHF	Total
Total assets	\$ 34,423,672	\$ 819,759	\$ 35,243,431
Total liabilities	642,171	40,605	682,776
Net assets: Unrestricted fund Externally restricted fund Endowment fund	11,258,636 20,929,190 1,593,675	554,879 224,275 -	11,813,515 21,153,465 1,593,675
Total net assets	\$ 33,781,501	\$ 779,154	\$ 34,560,655

The following is a summary of the revenue and expenses of each entity for the years ended March 31, 2022:

March 31, 2022		RCHF	QPHF	Total
Revenue Expenses	;	\$ 15,660,738 11,707,481	\$ 149,800 131,469	\$ 15,810,538 3,558,062
Excess of revenue over expenses	,	\$ 3,953,257	\$ 18,331	\$ 12,252,476

4. Cash and cash equivalents:

Cash and cash equivalents include restricted gaming funds of \$460,739 (2022 - \$410,890).

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

5. Investments:

	2023	2022
Core active bond funds, held at fair value	\$ 10,231,244 11,134,561	\$ 9,915,038 10,968,274
Global equity pooled funds, held at fair value Global equity funds, held at fair value	248,381	243,917
Canadian equity pooled fund, held at fair value Canadian equity fund, held at fair value	7,380,058 61,894	7,672,250 65,207
Canadian income fund, held at fair value Dividend income funds, held at fair value	50,101 145,796	53,244 152,041
Money Market fund, held at fair value Multi credit fund, held at fair value	326,876 1,449,295	317,982 1,438,458
Bond funds, held at fair value	236,705	245,217
	\$ 31,264,911	\$ 31,071,628

6. Tangible capital assets:

				2023	2022
		Ac	cumulated	Net book	Net book
	Cost	aı	mortization	value	value
Building	\$ 469,933	\$	50,909	\$ 419,024	\$ 434,849

7. Investment in FCT:

In December 2019, the Foundation acquired control of FCT by way of gifts of shares from five donors.

	2023	2022
Investment balance, March 31, 2022 Equity gain (loss)	\$ 750,089 85,674	\$ 505,464 244,625
Investment balance, March 31, 2023	\$ 835,763	\$ 750,089

Financial information for FCT for the year ended March 31, 2023 is summarized as follows:

	2023	2022
Total assets Total liabilities	\$ 1,108,558 822,143	\$ 1,035,299 825,056
Shareholder's equity	\$ 286,415	\$ 210,243

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

7. Investment in FCT (continued):

	2023	2022
Total revenue Total expenses	\$ 1,170,959 1,085,285	\$ 945,618 700,993
Net income	\$ 85,674	\$ 244,625
	2023	2022
Cash flows from operations	\$ (75,275)	\$ (239,399)
Total cash flows	\$ (75,275)	\$ (239,399)

The Foundation received \$30,000 (2022 - \$30,000) of rental income from FCT which is included in other income. This transaction is considered to be in the normal course of operations and is measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties and is at or below fair value.

8. Externally restricted funds:

	2023	2022
Capital funds:		
Arthur & Irene Bourassa Fund	\$ 2,577,034	\$ 2,575,098
William McKerracher Fund	1,180,151	1,179,266
Meehan Story Fund	1,092,221	1,091,401
Anne & Andrew Park Capital Fund	681,183	680,672
Tom & Mary Hobbis Capital Fund	108,076	107,995
	5,638,665	5,634,432
Designated funds	25,452,826	15,519,033
	\$ 31,091,491	\$ 21,153,465

The capital funds are externally restricted. Revenues earned on related investments shall be used for the purposes of the funds or added to the principal of the funds. The principal, designated by the donor, can be used for capital equipment acquisitions, renovations of facilities and staff and patient education at Royal Columbian Hospital, as set out in the bylaws of the Foundation. Board approval is required for the use and timing of use of the principal. The bylaws state the principal of the capital fund shall only be utilized after a written resolution of the Board is passed by a minimum of two thirds of the entire Board. The principal of the Arthur & Irene Bourassa Fund cannot be utilized until the year 2032.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

9. Endowment funds:

	2023	2022
Wintemute Family Memorial Fund Blake & Alisa Rowson Fund (a)	\$ 503,419 349,344	\$ 503,045 340,807
Florence Leitch Cotton Education Fund (a)	260,261	248,193
J.S. (Jack) and Gertrude Dennis Family Endowment Fund	125,856	125,761
C.M. "Tip" Robertson Memorial Endowment Fund	112,553	112,468
Hazel Emerson Nursing Education Fund Cardiovascular Epidemiology Research Fund	111,456 64,431	111,372 64,383
Dr. Andrew Tan Memorial Endowment Fund	37,997	37,968
Royal Columbian Hospital Nursing Alumnae G. MacPhail	20,434	20,419
Reginald Skelton Endowment Fund	15,622	15,610
Fred Withers Endowment Fund	19,019	13,649
Dr. Meghan Roberts Scholarship Endowment Fund	20,015	-
	\$ 1,640,407	\$ 1,593,675

The endowment funds are to be held by the Foundation in perpetuity and any associated revenue is to be used for the designated purpose of each fund or added to the principal of the funds. Investment income from the funds is restricted as follows:

- The Wintemute Family Memorial Fund and the J.S. (Jack) and Gertrude Dennis Family Endowment Fund are for the purpose of capital expenditures for Royal Columbian Hospital.
- The Blake & Alisa Rowson Fund is to support the introduction of innovative health care services.
- The Florence Leitch Cotton Education Fund is to support professional development for nursing staff at Royal Columbian Hospital.
- The C.M. "Tip" Robertson Memorial Endowment Fund is for the acquisition of capital equipment and renovations of facilities at Royal Columbian Hospital.
- The Hazel Emerson Nursing Education Fund is to support registered nurses in the psychiatric and medical areas of Royal Columbian Hospital.
- The Cardiovascular Epidemiology Research Fund is to support patient education and awareness of cardiovascular diseases.
- The Dr. Andrew Tan Memorial Endowment Fund is to support the Intensive Care Unit at Royal Columbian Hospital.
- The Royal Columbian Hospital Nursing Alumnae G. MacPhail Fund is to support an employee of Royal Columbian Hospital who is actively pursuing a Baccalaureate of Nursing Degree, Masters of Nursing Degree, or Specialty Certification and assist with education costs.
- The Reginald Skelton Endowment Fund is to support the Interventional Cardiology Program at Royal Columbian Hospital.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

9. Endowment funds (continued):

- The terms of reference for the Fred Withers Endowment Fund are being developed.
- The Dr. Meghan Roberts Scholarship Endowment Fund is to assist with one psychiatry resident's education costs per year.

(a) Interfund transfer:

The terms and conditions of the Blake & Alisa Rowson Fund and Florence Leitch Cotton Education Fund specify that unspent investment income earned on the endowment funds should be capitalized as part of the principal balance. In 2023, the Foundation recognized an interfund transfer of \$40,162 (2022 - \$24,024) to transfer the unspent investment income allocated to the designated funds as per the Foundation's policies to the endowment funds.

10. Investment income:

Investment income earned by the Foundation is comprised of the following:

	2023	2022
Dividend income Interest income Net foreign income Capital gains Capital gain distributed Unrealized loss	\$ 263,180 565,526 302,613 151,220 453,609 (1,226,276)	\$ 186,832 338,751 350,546 201,512 916,194 (521,512)
	\$ 509,872	\$ 1,472,323

11. Commitments:

During the 2022/23 fiscal year the Foundation made commitments to the Authority in order to purchase equipment, fund research and enhance patient care of \$9,561,947 (2022 - \$8,814,196). As of March 31, 2023, \$4,435,184 (2022 - \$1,334,202) of these commitments are still outstanding.

In addition, the Foundation has committed a minimum campaign target of \$39,100,000 to assist in the redevelopment of the Royal Columbian Hospital. Funds raised through donations that are specified by the donors to be used towards the redevelopment are held in the externally restricted fund. As at March 31, 2023, the Foundation has received a total of \$22,711,694 (2022 - \$14,649,603) in donations and an additional \$31,243,819 (2022 - \$6,933,647) in pledges have been made for the redevelopment. The Foundation has disbursed a total of \$10,164,602 (2022 - \$8,510,000) to the Authority for the redevelopment to date.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

12. Life insurance policy:

The Foundation is the beneficiary of one life insurance policy with a total expected final settlement value of \$100,000. The cash surrender value on the life insurance policy at March 31, 2023 is \$11,404 (2022 - \$11,404). The annual premium payment for the policy is paid by the donor on behalf of the Foundation.

13. Related party transactions and balances:

The amounts due from the Authority consist of donations collected by the Authority on behalf of the Foundation that are owing at year end.

The amounts due to the Authority consist of contributions that are unpaid as at year end.

In fiscal 2023, the Foundation contributed \$474,703 (2022 - \$305,465) of in-kind marketing and communication services to the Authority, and \$83,586 (2022 - \$115,161) of in-kind research innovation. These costs are classified as contributions to support the Authority in the non-consolidated statement of operations.

All amounts paid to or received from the Authority are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties and are at or below fair value.

14. Financial risks:

The Foundation manages its investment portfolio to earn investment income and invests according to an Investment Policy Statement approved by the Board. The Foundation is not involved in any hedging relationships through its operations and does not hold or use any derivative financial instruments for trading purposes.

The Foundation manages interest-rate, market, credit, foreign currency and cash flow risk from its investments by investing in a diversified portfolio.

Additionally, the Foundation believes it is not exposed to significant liquidity risk as all investments are held in pooled fund instruments that are highly liquid.

15. Employee Pension Benefits:

The Foundation and its employees contribute to the Municipal Pension Plan (the "Plan"), a jointly trusteed pension plan. The board of trustees, representing Plan members and employers, is responsible for administering the Plan, including investment of the assets and administration of benefits. The Plan is a multi-employer defined benefit pension plan. Basic pension benefits provided are based on a formula. The Plan has about 240,000 active members and approximately 124,000 retired members. Active members include 17 contributors from the Foundation.

Notes to Non-Consolidated Financial Statements (continued)

Year ended March 31, 2023

15. Employee Pension Benefits (continued):

Every three years, an actuarial valuation is performed to assess the financial position of the Plan and adequacy of plan funding. The actuary determines an appropriate combined employer and member contribution rate to fund the Plan. The actuary's calculated contribution rate is based on the entry-age normal cost method, which produces the long-term rate of member and employer contributions sufficient to provide benefits for average future entrants to the Plan. This rate may be adjusted for the amortization of any actuarial funding surplus and will be adjusted for the amortization of any unfunded actuarial liability.

The most recent actuarial valuation as at December 31, 2021 indicated a \$3.761 million funding surplus for basic pension benefits on a going concern basis. The next valuation will be December 31, 2024, with results available in 2025.

During fiscal 2023, the Foundation paid \$191,777 (2022 - \$191,091) for employer contributions to the Plan.

Employers participating in the Plan record their pension expense as the amount of employer contributions made during the fiscal year (defined contribution pension plan accounting). This is because the Plan records accrued liabilities and accrued assets for the Plan in aggregate with the result that there is no consistent and reliable basis for allocating the obligation, assets and cost to the individual employers participating in the Plan.

16. Interfund transfers:

The Foundation made transfers from the unrestricted fund to the designated fund of \$1,075,323 (2022 - \$844,122) and to the endowment fund of \$40,162 (2022 - \$24,024) for purposes as approved by the Board.

17. Remuneration of employees:

For the fiscal year ending March 31, 2023, the Foundation paid total remuneration of \$2,327,642 (2022 - \$2,129,208) to sixteen (2022 - sixteen) employees, each of whom received total annual remuneration of \$75,000 or greater.

The Foundation did not pay any remuneration to its Board of Directors.